Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06985953 · ClinicalTrials.gov registry record · NA

Evaluating the Communication Between Patients and Providers in Cancer Clinics

A NA study of Cancer, sponsored by University of Wisconsin, Madison.

Recruiting
Registry status
NA
Development phase
30
Enrollment target
3
Study locations

NCT06985953: Recruiting NA study of Cancer, sponsored by University of Wisconsin, Madison.

NCT06985953 is a NA study of Cancer that is actively recruiting participants, run by University of Wisconsin, Madison. The registered enrollment target is 30 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06985953, a NA study of Cancer, is actively recruiting participants, sponsored by University of Wisconsin, Madison.

RECRUITING
Registry status
NA
Development phase
30 participants
Enrollment target
3
Study locations

Study Summary

This clinical trial seeks to understand patients' experiences with the healthcare team and the quality of communication between patients and doctors in cancer clinics. The main question it aims to answer is: * Does TrialTalk™ improve communication between providers and patients? Participants will complete questionnaires before and after their standard of care clinic visit.

Primary Outcome

Fidelity to the tool by providers is measured by a 9 item qualitative questionnaire, asking how many times and how providers used TrialTalk™ when talking with their patients.

Conditions Studied

Interventions

  • OTHER TrialTalk™

Study Locations (3)

Illinois

  • Northwestern Memorial Hospital - Chicago

South Carolina

  • Medical University of South Carolina - Charleston

Wisconsin

  • University of Wisconsin - Madison - Madison

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2026-03
Est. Completion 2027-02
Phase NA
University of Wisconsin, Madison

1,039 total trials

What NCT06985953 shows while recruiting

NCT06985953 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower).

The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which TrialTalk™ is the first listed.

NCT06985953 reports a single indexed study location in Illinois, South Carolina, Wisconsin.

Frequently Asked Questions

What is clinical trial NCT06985953 about?

NCT06985953 is a clinical study titled "Evaluating the Communication Between Patients and Providers in Cancer Clinics". This clinical trial seeks to understand patients' experiences with the healthcare team and the quality of communication between patients and doctors in cancer clinics. The main question it aims to answer is: * Does TrialTalk™ improve communication between providers and patients? Participants will ...

What is the current status of trial NCT06985953?

This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2026-03. Estimated completion is 2027-02.

What conditions does trial NCT06985953 study?

This clinical trial studies the following conditions: Cancer.

What interventions are being tested in trial NCT06985953?

The interventions under investigation include: TrialTalk™ (OTHER).

Who is sponsoring clinical trial NCT06985953?

This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06985953 being conducted?

This trial has 3 study locations across Illinois, South Carolina, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06985953's enrollment target sits among peer trials

30 502nd of 615 higher than 93 of 615 other Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT06985953, the US trial registry maintained by the National Library of Medicine. NCT06985953 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.